1. – Progesterone receptor A-regulated gene expression in mammary organoid cultures. Santos SJ, Aupperlee MD, Xie J, Durairaj S, Miksicek R, Conrad SE, Leipprandt JR, Tan YS, Schwartz RC, Haslam SZ. J Steroid Biochem Mol Biol. 2009;115(3-5):161-72. This experimental study used breast cells from mice, cultured in vitro. First, the behavior of the cells was compared after exposure to either progesterone or the synthetic progestin, promogestone. After seeing similar proliferation with both progestogens, they then went on to conduct gene expression studies (again in the mouse mammary cells) using only the promogestone. They found that certain genes were activated by the promogestone, and these were regulated by progesterone receptor A,.
Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study OBJECTIVE: Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women. Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established. CONCLUSIONS: This large study found that route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk among postmenopausal women using hormone therapy. Transdermal estrogens alone or combined with progesterone might be safe with respect to thrombotic risk. Source: http://www.ncbi.nlm.nih.gov/pubmed/19834106?dopt=Abstract
The PROMISE trial First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double-blind placebo-controlled multi-centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). Anticipated end date of trial is May 2012. Countries of recruitment: Netherlands, United Kingdom. Study hypothesis In women with unexplained recurrent miscarriages, progesterone (400 mg pessaries, twice daily), started soon as possible after a positive pregnancy test (and no later than 6 weeks gestation) and continued to 12 weeks of gestation, compared to placebo, increases live births beyond 24 completed weeks by at least 10% (principal objective) Progesterone improves secondary outcomes such as gestation at delivery, on-going pregnancy at 12 weeks,.
A clinical trial published in last month’s International Journal of Pharmaceutical Compounding showed strong symptom relief and minimal side effects with progesterone treatment. This study is in line with numerous others conducted throughout the years reinforcing the benefits of bioidentical progesterone. Abstract: This study explored the perspective of women using compounded progesterone preparations. Semi-structured interviews were conducted in Victoria, Australia with eight self-selected women who were dispensed a progesterone-only preparation. Participating women gained symptom relief for migraine, painful breasts, mood swings, bloating, hot flushes, and other conditions. The participants also experienced unexpected benefits such as improvement in irregular and painful periods, relief from cystitis, or increased libido, without any reported.
USA Today, March 2010 A small study of bioidentical progesterone in the treatment of traumatic brain-injured patients was so promising the National Institutes of Health has financed a larger, nationwide study that is to start enrolling patients this week. Scientists are still trying to unravel how progesterone protects the brain, but laboratory and animal studies suggest that it is critical for normal development of brain cells and reduces swelling from trauma. The NIH is betting at least $14 million, the cost of the first three years of the expanded trial, that progesterone will pan out, he says. The new trial plans to randomly assign a total of 1,140 newly brain-injured.